



0220
#8

PATENT

Attorney Docket No.: 8321-90

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Patent application of :
Ziwei Huang, et al. :
Serial No.: 09/773,830 : Group Art Unit: Unknown
Filed: February 1, 2001 : Examiner: Unknown
For: A Novel Peptide Antagonist of CXCR4- :
Derived from the N-Terminus of Viral :
Chemokine vMIP-II :

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37C.F.R. §§1.97-1.98, submitted herewith are copies of the reference listed in the accompanying Form PTO-1449.

The Examiner is respectfully requested to review the items listed on the attached PTO 1449 and make them of record in the instant application as required by M.P.E.P. §609. It is requested that the Examiner initial the enclosed duplicate substitute Form 1449, and return one copy to the undersigned.

CERTIFICATE OF MAILING
UNDER 37 C.F.R. 1.8(a)

I hereby certify that this paper, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date indicated below, with sufficient postage, as first class mail, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231.

BY

Jackie Williams


DATE:

8/27/02

This Information Disclosure Statement should not be construed as a representation that the cited references are material or that more relevant prior art does not exist.

This Statement is being submitted before receipt of any office action on the merits. Also, each listed item was first cited in a communication from a foreign patent office in a counterpart foreign application, not more than three months prior to the filing of the herein information disclosure statement. Thus, no fee is due for the filing of this paper. However, if a fee is due, please charge deposit account 50-0573.

Respectfully submitted,
ZIWEI HUANG, et al.

By: 
DANIEL A. MONACO
Registration No. 30,480
DRINKER BIDDLE & REATH, LLP.
One Logan Square
18th and Cherry Streets
Philadelphia, PA 19103-6996
(215) 988-3312
(215) 988-2757 – Fax

Attorney for Applicants

SUBSTITUTE FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY.' DOCKET NO.
8321-90SERIAL NO.: Not Yet Assigned
09/773,830

INFORMATION DISCLOSURE CITATION

APPLICANT: **Ziwei Huang, et al**FILING DATE February 1,
2001GROUP
Not Yet Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	AA						
	AB						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	NO
	AC							
	AD							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AE	Liwang, et al.: "The Solution Structure of the Anti-HIV Chemokine vMIP-II" <i>Protein Science</i> Vol. 8, pp. 2270-2280 (1999) Cambridge University Press (USA).
AF	Luo, et al. "The Role of Positively Charged Residues in CXCR4 Recognition Probed with Synthetic Peptides" <i>Biochemical and Biophysical Research Communications</i> Vol. 263, pp. 691-695 (1999) Academic Press (USA)
AG	Fernandez, et al.: "Comparison of the Structure of yMIP-II with Eotaxin-1, RANTES, and MCP-3 Suggests a Unique Mechanism for CCR3 Activation" <i>Biochemistry</i> Vol. 39, pp.12837-12844 (September 26, 2000) American Chemical Society (USA)
AH	Luo, et al.: "Structure-Function Study and Anti-HIV Activity of Synthetic Peptide Analogues Derived from Viral Chemokine vMIP-II" <i>Biochemistry</i> Vol. 39, pp.13545-13550 (October 6, 2000) American Chemical Society (USA)
AI	Zhou, et al.: "Exploring the Stereochemistry of CXCR4-Peptide Recognition and Inhibiting HIV-1 Entry with D-Peptides Derived from Chemokines" <i>The Journal of Biological Chemistry</i> Vol. 277, No. 20, (2002), American Society for Biochemistry and Molecular Biology, Inc. (USA)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.